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Abstract 
Background: Translational science supports successful transition of early biomedical research into human applica-
tions. In 2009 a translatability score to assess risk and identify strengths and weaknesses of a given project has been 
designed and successfully tested in case studies. The score elements, in particular the contributing weight factors, are 
heterogeneous for different disease areas; therefore, the score was individualized for six areas (cardiovascular, oncol-
ogy, psychiatric, anti-viral, anti-bacterial/fungal and monogenetic diseases).
Results: FDA reviews and related literature were used for modifications of the score with emphasis on biomarkers, 
personalized medicine and animal models. 113 new medical entities approved by FDA from 2012 through 2016 were 
evaluated and metrics obtained for companion diagnostics and animal models as starting points for author-based 
individualization of the score. Most drugs approved in this period were related to oncology (46%), while the approv-
als were lowest for psychiatrics (4%). The evaluation of the FDA package inserts revealed that companion diagnostics 
play an important role in every field except psychiatrics. Further the analysis of the FDA reviews showed the weakness 
of animal models in psychiatrics and anti-virals, while useful animal models were present for all other fields. Con-
sequently the scoring system was adapted to the different fields, resulting in increased weights for animal models, 
biomarker and personalized medicine in oncology. For psychiatrics the weights for animal models, biomarker and 
personalized medicine were decreased, while the weight for model compounds, clinical trials and surrogate or end-
point strategy were increased. For anti-viral drugs weights for in vitro data and personalized medicine were increased, 
while the weight for animal models was decreased. Further, for anti-bacterial/fungal drugs weights for animal models 
and personalized medicine were increased. Weights were increased for genetics and personalized medicine and 
decreased for model compounds for monogenetic orphans.
Conclusions: Adaptation of the score to different disease areas should help to support a structured and diverse 
approach to translation and encourage researchers in the private or public sectors to further customize the score.
Keywords: Translational science, Translatability scoring, Cardiovascular, Oncology, Psychiatric, Anti-infectives, 
Monogenetic orphans, Personalized medicine, Companion diagnostics, Animal models
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Background
Translational science is an important component of 
drug development aiming at the reduction of burgeon-
ing timelines and costs mainly driven by late attrition in 
Phase II and III clinical trials [1]. It describes the transi-
tion of in vitro and in vivo data into human applications 
[2]. Understanding the biological evidence and clinical 
data supporting target selection is crucial and provides a 
basis for validation or invalidation of a scientific hypothe-
sis [3]. One of several approaches to improve drug devel-
opment is the casting of a translatability score published 
in 2009 to assess the availability and quality of in  vitro 
and in vivo results, clinical data, biomarkers and person-
alized medicine issues [4]. Here we describe refined scor-
ing templates tailored to reflect the diverging importance 
of scoring items in different therapeutic areas.
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In brief, the original score [4] adds different items cat-
egorized between 1 and 5 and multiplied by a weight fac-
tor reflecting the importance of each item. The weight 
factors are generally higher for all items on human data, 
as positive clinical data are more indicative of successful 
drug development than in vitro or in in vivo animal data. 
Biomarkers play an important role in the score and a 
separate score for biomarkers is included. This biomarker 
score reflects animal and human data, their proximity to 
the disease, accessibility and test validity parameters such 
as sensitivity and specificity [5]. Any sum score of the 
translatability scoring system above four is indicative of 
fair to good translatability and low risk.
Other groups addressed the idea that a structured 
approach to guide and improve translation is much supe-
rior to the more inspirational ‘gut feeling’ approach of 
former times. Cook et  al. [3] developed a system which 
basically includes the same criteria, the 5R framework. It 
was developed in reflection of AstraZeneca’s recent pipe-
line and seemed to tentatively improve success indicators 
of drug development after implementation.
An analysis of data from Phase II decisions for 44 pro-
grams at Pfizer revealed that success in Phase II clinical 
development is mainly related to drug exposure at the 
site of action, target binding and expression of func-
tional pharmacological activity [6]. Their system called 
‘three pillars of survival’ shares similarities with our 
score though being limited to a smaller number of items. 
The extent to which our system has influenced others in 
similar approaches is not clear; it has been cited in those 
papers above and earlier by a Pfizer group reporting on 
the highly structured and sophisticated data integrating 
approach described in [7]. It seems that it has at least 
supported the wider acceptance of structured and metric 
approaches in pharmaceutical decision making.
As prospective validation is hard to obtain (estimated 
study time  >  8  years) and, thus, largely missing for all 
structured approaches so far, we retrospectively tested 
our score in eight case studies; they seemed to support 
the hypothesis that this score may indeed have prognos-
tic power [8]. However, these cases from different disease 
areas already showed that the importance of in vitro and 
animal in  vivo studies, clinical studies, biomarkers and 
personalized medicine may substantially vary between 
the disease areas. For example, considerable differences 
between oncologic and psychiatric diseases exist: as 
opposed to malignant diseases, high profile translational 
biomarkers are largely missing in psychiatric diseases. 
The underlying molecular mechanisms are increasingly 
well understood in oncology [9], which is not the case in 
psychiatric diseases. These deficiencies encumber drug 
development in latter area [10] resulting in a sparsely 
populated pipeline and low probability of approval (6.2%) 
[11]. In contrast, the molecular mechanisms of mono-
genetic orphan diseases are widely understood which 
is also reflected in the likelihood of approval (25.3% for 
all rare diseases, not only including monogenetics) [11]. 
Drugs against infectious diseases also have a high likeli-
hood of approval (19.1%) [11] as their efficacy against 
microbes can be tested in  vitro. Personalized medicine 
aspects are more important in the genetically heteroge-
neous fields of oncology compared to cardiovascular dis-
eases for example.
Methods
The translatability score published in 2009 [4] was cus-
tomized to different areas of disease (cardiovascular, 
oncology, psychiatric, anti-viral, anti-bacterial/fungal and 
monogenetic orphans) on the basis of the FDA reviews, 
package inserts and related literature dealing with the 
drugs approved from 2012 to 2016.
For the evaluation of companion diagnostics (CDx) the 
FDA package inserts for the different drugs were evalu-
ated. In our definition CDx are tests that provide infor-
mation being essential for the safe and effective use of a 
corresponding drug or biological product in patients, 
including diagnosis, safety, efficacy and therapeutic 
monitoring. This does not apply to tests for basic safety 
monitoring like blood counts, liver enzymes etc. Tests in 
which specialized monitoring is necessary to safely apply 
a drug (such as coagulation factor determination for fac-
tor replacement therapy) were included in the assess-
ment. Diagnostic tests were included if essential for the 
specific treatment (such as resistance testing for anti-
viral drugs, the determination of receptor status in oncol-
ogy and the detection of the corresponding genetic cause 
of a disease, especially in the monogenetic orphans).
For the evaluation of animal models the pharmacol-
ogy reviews of the FDA were analyzed for cardiovascular, 
oncology, psychiatric and monogenetic orphans and the 
microbiology/virology. Only animal models for efficacy 
were analyzed and the number of animal models used 
was calculated. Further the percentages of total numbers 
were calculated for positive outcome prediction by ani-
mal models as stated in the FDA reviews and averages 
were displayed.
Results
Drug approvals in 2012–2016
FDA market approvals for the years 2012–2016 were 
analyzed to define the importance of the score items for 
the following six disease areas: cardiovascular, oncology, 
psychiatric, anti-viral, anti-bacterial/fungal and monoge-
netic orphan diseases (Additional file 1: Tables S1–S6).
During that time span oncology approvals were most 
frequent (46%, Fig.  1a), while in psychiatrics only 4% of 
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the total number were approved (Fig. 1a). This is in line 
with a relatively low likelihood of approval of 6.2% in psy-
chiatrics determined for earlier years (2006–2015) [11]. 
Oncology drugs had a twofold higher rate of first cycle 
approval than psychiatric drugs, which had the lowest 
first cycle review approvals [11]. For infectious diseases 
the likelihood of approval is high with 19.1% [11], while 
numbers of approval in our sample (anti-viral: 9%, anti-
bacterial/fungal: 10%) are lower than in cardiovascular 
(16%), and monogenetic orphan diseases (15%, Fig.  1a). 
The number of approved drugs depends on the num-
ber of drugs in the pipeline which is highest for oncol-
ogy [12], therefore resulting in high approval numbers 
despite the low likelihood of approval (5.1% [11]). The 
astonishingly low likelihood of approval for oncology 
could be partially due to commercial decisions and port-
folio prioritization [11, 13].
Oncology has the highest percentage of total US 
approvals in every analyzed year (Fig. 1b, primary y-axis, 
continuous lines). For the monogenetic orphans there is 
a trend towards more approvals (Fig. 1b, primary y-axis, 
continuous lines), which may be due to the intense sup-
port of the development of drugs against orphan diseases 
by the FDA.
Analyzing the different years there is a peak of total 
approvals in 2015, with a remarkable decrease in 2016 
oncology
46%
cardiovascular
16%psychiatric
4%
an-viral
9%
an-bacterial/fungal
10%
monogenec 
orphans
15%
0
5
10
15
20
25
30
35
40
45
50
0
10
20
30
40
50
60
70
80
2012 2013 2014 2015 2016
oncology
cardiovascular
psychiatric
an-viral
an-bacterial/fungal
monogenec orphans
total numbers of US
approvals
%
 o
f t
ot
al
 U
S 
ap
pr
ov
al
sa
sp
er
 y
ea
r
To
ta
l n
um
be
rs
 o
f U
S 
ap
pr
ov
al
sa
s p
er
 y
ea
r
a
b
Fig. 1 Drug approvals in 2012–2016. a Approvals in percent of total analyzed drugs as per therapeutic area. b US Drug approvals as per year. 
Primary y-axis (continuous lines): approval in percent of total US approvals as per year, secondary y-axis (broken line): total numbers of US approvals 
as per year
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(Fig. 1b, secondary y-axis, broken line). In total (includ-
ing all areas of disease) there have been only 22 approvals 
in 2016 compared to 30 in average in the years 2007–
2015 [14]. The same trend was true for approvals by the 
EMA [15]. This may be due to the fact that some of the 
drugs which have been approved in 2015 have been origi-
nally scheduled for 2016, and for some, which have been 
scheduled to 2016 approval has been delayed, due to 
more complete response letters issued by the FDA. These 
letters were often addressing deficiencies in good manu-
facturing practice [16].
Companion diagnostics are important in drug 
development
Biomarkers are important in many translational aspects 
and contribute 50% to the total translatability score if 
weight factors of related items (biomarker grading, bio-
marker development, biomarker strategy, surrogate or 
end point strategy) are added. Therefore, the use of bio-
markers in the process of drug development has been 
evaluated in particular. Companion diagnostics play an 
increasingly important role in drug development and 
point to essential biomarkers as a conditio sine qua non, 
with a particular emphasis on personalized medicine.
Companion diagnostics is not a completely new phe-
nomenon though very fashionable today. The use of tests 
to guide the effective and safe use of drugs is an essen-
tial part in the process of patient care and has been 
performed for a long time. Examples are glucose-6-phos-
phate-dehydrogenase deficiency testing and Rasburicase 
[15], or the identification of defective clotting factors for 
the diagnosis and treatment of patients with coagulation 
disorders. CDx was widely recognized only with the suc-
cess of trastuzumab and imatinib [17].
There is no consistent definition of CDx [17]. For our 
definition see “Methods”. The definition of the FDA for 
CDx is stricter: A companion diagnostic is a medical 
device, often an in  vitro device, which provides infor-
mation that is essential for the safe and effective use of 
a corresponding drug or biological product, includ-
ing identification of the right patient and monitoring 
response. The use of a companion diagnostic device 
with a particular therapeutic product is stipulated in the 
instructions for use in the labeling of both the diagnostic 
device and the corresponding therapeutic product [18].
In our extended definition, all assays mentioned in 
the FDA package insert dealing with efficacy, safety 
and/or monitoring were considered to be CDx, even if 
not explicitly mentioned and not found to be mandato-
rily tested by an FDA approved device. CDx have been 
found in all disease areas except psychiatrics (Fig. 2, col-
umn 1) as alluded to above. In our sample CDx stipu-
lated mandatory in the FDA package insert were only 
present in oncology (Fig.  2, column 2). Our definition 
results in a high number of CDx for anti-infectives 
and monogenetic orphans, as susceptibility, hypersen-
sitivity, resistance testing or underlying genetic cause 
should be tested for prior to therapy. The fraction of 
CDx is particular high for anti-viral drugs, as most of 
the approved drugs in the evaluated time period have 
been drugs against HIV or HCV (Additional file 1: Table 
S4), requiring resistance testing or genotyping, respec-
tively. Therefore all tests for the anti-virals are genetic 
assays (Fig.  2, column 3). In contrast, there were no 
genetic tests for anti-bacterial/fungal drugs, as the rec-
ommended or necessary tests are dealing with suscepti-
bility (antibiograms). For cardiovascular, oncology and 
monogenetic orphans, genetic tests are needed in some 
cases (Fig.  2, column 3) but also other tests, including 
enzymatic tests (Additional file  1: Tables S1, S2, S6), 
may be recommended. The high number of CDx in 
monogenetic orphans is due to the fact that the under-
lying genetic cause has to be analyzed using genetic or 
enzymatic tests to get a clear diagnosis.
In order to develop CDx, good understanding of the 
underlying mechanisms for the disease is important. If 
this is the case the likelihood for success is much higher 
so that it is not astonishing that the probability of suc-
cessful transition from phase I to approval is 25.9% for 
drugs coming with a CDx test compared to 8.4% for 
drugs without predictive biomarker [11]. As evident in 
Fig. 2, the lack of CDx for psychiatrics is in line with the 
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Fig. 2 Analysis of FDA data on companion diagnostics (CDx) for 
drugs approved from 2012 to 2016. Total CDx: percentage of drugs 
with CDx as defined in text. CDx stipulated as mandatory in the FDA 
insert: percentage of drugs with CDx mandated by the FDA as stipu-
lated in the package insert genetic testing: percentage of drugs with 
CDx representing genetic tests
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lack of biomarkers as a general feature of this disease 
area.
CDx may further facilitate the clinical studies as a 
smaller number of patients may be needed to show 
an effect, saving resources and time spent on clinical 
development [17]. The use of a biomarker in phase III 
increases the success to 62% compared to 28% overall 
success rate in phase III [11].
The potential of CDx in development will be mainly 
reflected in biomarker-related items of the scoring 
approach [5].
Disease‑area related differences in the predictivity 
of animal models
Animal models are important to provide data on safety 
and efficacy (so-called animal-PoC, proof of concept) 
at the preclinical level; yet, there are large differences 
regarding availability and usefulness of animal mod-
els between disease areas. The average number of ani-
mal models reported for efficacy varied considerably 
between disease areas ranging from 0.4 to 8.4 (Fig.  3a). 
While relatively few different animal models could be 
found for oncology, cardiovascular, anti-viral and mono-
genetic orphan drugs, larger numbers of models have 
been reported for psychiatrics and anti-bacterial/fun-
gal drugs. Despite the multitude of animal models used 
in psychiatrics, the average number of positive results 
translating into human findings was lowest in this area 
(Fig.  3b), indicating a low predictivity of animal models 
into clinical trials. In the other areas the contribution of 
animal models to translation was higher, as indicated by 
a greater rate of successful translation (Fig. 3b). The small 
number animal models tested for anti-viral drugs seems 
to reflect the fact that most of the approved drugs are 
treating HIV or HCV (Additional file 1: Table S4), which 
are highly specific for humans, and, therefore, animal 
models are not required by the FDA [19, 20]. The large 
number of animal models used to develop anti-bacterial/
fungal drugs reflects the need for testing many differ-
ent infection models including those on different sites of 
infection and sepsis (Additional file 1: Table S5).
Though not particularly prevalent in the sample of drug 
approvals analysed here, the weight factor for animal evi-
dence should be increased (doubled or even tripled) case 
by case if primate studies were performed; they however 
cannot replace the value of human studies though their 
predictivity is certainly much higher than that of e.g. 
rodent studies.
Adaptation of the translatability score to different disease 
areas
Based on the evaluation of the FDA reviews and related 
literature the translatability scoring system published 
2009 [4] has been modified for different disease areas 
with particular emphasis on biomarkers and animal 
models as described above. Changes of weight factors 
were mainly driven by these aspects with weight changes 
for other aspects being adapted oppositely to keep the 
sum of weight factors at 100%. Changes in the weights 
differing by more than two points from the original are 
highlighted in italic (Table 1).
Changes in the weights of the score have been per-
formed according to the results of the FDA reviews and 
package inserts. Important weights were doubled (model 
compounds, clinical trials for psychiatrics), tripled (dis-
ease sub-classification and responder concentration, 
or quadrublicated (genetics for monogenetic orphans). 
Weights for points which are less important have been 
reduced. As the overall score needs to be 100 all other 
scores have been adapted accordingly.
The weights for cardiovascular diseases have been 
left unchanged, as the original score has been devel-
oped against a cardiovascular background. For oncology 
0
2
4
6
8
10
12
0
20
40
60
80
100
120
%
of
 to
ta
l e
xp
er
im
en
ts
 
w
ith
 p
os
i
ve
ou
tc
om
e
To
ta
l n
um
be
rs
a
b
Fig. 3 Animal models described in FDA reviews for drugs approved 
from 2012 to 2016. a Average total numbers of animal models used 
in different therapeutic areas as described in the FDA reviews. For 
xenograft studies experiments in same animals but using different 
cell lines were considered as one model. Different variants of nude 
mice were also considered as one model as the underlying principle 
is the same. Orthotopic or epitopic xenografts were considered as 
different models according to the classification of Ruggeri et al. [30]. 
b Percentages of total numbers were calculated for positive outcome 
prediction by animal models as stated in the FDA reviews; averages 
for disease areas are shown
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the weight of animal models has been increased, as our 
evaluation of the FDA reviews showed a good correla-
tion between animal and clinical data (Fig.  3 and Addi-
tional file  1: Table S2). It is however of concern that a 
publication bias might exist for animal models as possibly 
not all negative results may have been discussed in the 
FDA documents. The weight for personalized medicine 
aspects and biomarkers have been increased in oncol-
ogy in reflection of a large prevalence of CDx (45.1% of 
all oncology drugs, 23.5% stipulated as being mandatory 
by the FDA) this points to the high relevance of personal-
ized medicine in oncology [21].
The weights for the starting evidence in psychiatric 
diseases have been reduced as reliable animal models 
and in vitro testing hardly exist (Fig. 3, Additional file 1: 
Table S3 and [22, 23]). The weights for model com-
pounds which already made it into human application 
and clinical trials have been increased; this reflects the 
lack of animal models and suitable biomarkers render-
ing human evidence particularly important. Biomarkers 
for safety and efficacy are very difficult to develop in psy-
chiatric diseases [10] and accordingly the weights of the 
related items (starting evidence, biomarkers for efficacy 
and safety prediction, biomarker strategy and personal-
ized medicine) have been lowered. Surrogate or endpoint 
strategy scoring has been doubled, as the lack of animal 
models renders the surrogate or endpoint strategy espe-
cially important. The weights for personalized medicine 
aspects have been lowered since CDx are not found in 
this category (Fig. 2, Additional file 1: Table S3).
For virus-borne diseases the weight for in  vitro data 
has been increased, while the weight of animal models 
has been decreased. Many viruses are highly specific for 
humans (for example HIV and HCV) and therefore reli-
able animal models are lacking. For example for HIV 
several animal models are available but none of them 
adequately reflects the human HIV [24]. This results in 
a greater importance of in vitro testing in this field. Fur-
ther in vitro testing is well established for anti-viral (and 
anti-microbial) drugs [25]. Additionally the aspect of 
personalized medicine is quite important in this field 
e.g. HIV- or HCV-mediated diseases require special test-
ing for resistance or genotyping, respectively (Additional 
file 1: Table S4).
For bacteria- and fungi-mediated diseases several relia-
ble animal models exist (Fig. 3, Additional file 1: Table S5 
Table 1 Modified weight factors (in percent) for the items of the translatability score in the different disease areas
Deviations from the original = cardiovascular score by more than two points are in italic
Original = cardio‑vascular Oncology Psychiatric Anti‑viral Anti‑bacterial/fungal Monogenetic orphans
Aspect
Starting evidence
  In vitro data including 
animal genetics
2 2 1 9 3 2
  In vivo data including 
animal genetics
3 1 1 1 5 2
  Animal disease models 3 5 1 1 5 2
  Data from multiple species 3 1 1 1 1 2
Human evidence
  Genetics 5 5 4 4 4 20
  Model compounds 13 10 26 12 12 2
  Clinical trials 13 11 26 12 12 10
Biomarkers for efficacy and safety prediction
  Biomarker grading 24 28 10 23 22 23
  Biomarker development 13 17 5 12 11 12
Proof-of-mechanism, proof-of-principle and proof of concept testing
  Biomarker strategy 5 5 7 5 5 5
  Surrogate or endpoint 
strategy
8 2 12 7 7 7
Personalized medicine aspects
  Disease sub-classification 
and responder concen-
tration
3 7 2 9 9 9
  Pharmacogenetics 5 6 4 4 4 4
  Sum 100 100 100 100 100 100
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and [26]), so that the weight for this aspect is higher than 
for anti-viral drugs. The aspect of personalized medicine 
is also quite important in this field due to susceptibility 
testing [27] and therefore the weight has been increased 
for this aspect.
For orphan genetic diseases animal models often exist 
(Fig. 3, Additional file 1: Table S6) as they do in cardio-
vascular diseases, so that the related weight has been left 
unchanged. The weight of human evidence, especially 
genetics, has been increased as by definition monoge-
netic orphan diseases always have a known genetic cause; 
this knowledge facilitates the translational process. The 
weight for model compounds has been lowered, since 
orphan drugs are mostly first in class drugs. Further the 
score for personalized medicine has been increased, as 
specific testing for the underlying genetic disease is per-
formed in most cases.
Discussion
The adaptation of the original translatability score 
reflects the varying requirements and challenges for the 
different disease areas in the translational process of drug 
development. In particular, it is obvious that biomark-
ers are indispensable for effective drug development, as 
they play a role in nearly all aspects of translation. Lack 
of knowledge on molecular mechanisms and the related 
absence of strong biomarkers result in low approval rates, 
as exemplified for psychiatric diseases.
The adaptations made should serve as suggestions on 
how the score might be modified before using it in a 
structured approach for a specialized area of biomedi-
cal research. The reasoning for these changes is based on 
an analysis of disease area-specific characteristics which 
may be done in an analogous way for other areas, and 
even adapted to the development of medical devices and 
diagnostics.
It, however, has to be emphasized that the changes of 
weight factors are subjective suggestions by the authors 
in reflection of the described analysis of drug approval 
data; no exact method could be identified to sup-
port these changes in a quantitative, metrical way. The 
approach chosen here, however, still seems to be useful 
to translate the area-specific peculiarities and encourage 
pharmaceutical scientists to modify them according to 
their own assessment and rating.
The rapidly emerging use of induced pluripotent stem 
cells may help to get valuable data in an early stage of 
drug development; these cells provide a rich source of 
patient-derived characteristics to screen for experimental 
drugs and profile them against patient-specific patholo-
gies [28]. If proven to yield in highly translatable research 
results their contribution to the translatability score 
needs to be revised e.g. by increasing the weight factors 
relating to in vitro evidence.
It should also be mentioned that—beyond predictive 
approaches such as the one described here implying the 
usefulness of a general model—translation should also be 
driven from the statement and delineation of the particu-
lar problem to be solved. It should not solely based on 
paradigmatic solutions reflecting translational problems 
in other projects.
Predicting clinical responses to novel checkpoint 
inhibitors, cancer vaccines, or T cell redirection strate-
gies is much more difficult due to the complexity of the 
substrate than predicting dependency on individual sig-
nal transduction pathways affected by well-characterized 
driver mutations [29]. The translational process never 
will be covered by a single static model or score, but must 
always be analyzed individually.
The scoring system should be applied after every major 
step of translation and adapted to the different require-
ments which may evolve in the different phases of pre-
clinical and clinical development as well. Its application 
will not only lead to a numeric score for a project at 
a given stage, but also identify strengths (high partial 
scores) and weaknesses (low partial scores) of this par-
ticular project. Beyond its value to assess the risk of a 
portfolio of projects, it should guide further research 
and efforts to specifically develop and address the weaker 
aspects of a project. Thus, its prospective use will not 
only support portfolio decisions (kill or thrive) but also 
induce improvement strategies of high risk projects 
which should not be killed as they often promise the larg-
est gains or leap innovations.
Conclusions
  • Drug development is highly complex and between 
disease areas or even within the same disease area 
important differences may exist; thus, the translat-
ability score requires adjustments according to spe-
cific disease areas as provided here.
  • A scoring system should help scientists to adequately 
address the cornerstones of translation, to intensify 
research in weak areas and ultimately develop a risk-
balanced portfolio. As several similar approaches have 
been developed it is fair to assume that a structured 
approach to translation has been widely accepted to 
reflect the state-of-the art at least in industry.
  • A prospective study on the impact of such a struc-
tured approach would be highly desirable but diffi-
cult to perform as a control group without structured 
approach would be hard to find at present.
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